

Certolizumab pegol

Certolizumab pegol^[1] (CDP870, tradename **Cimzia**) is a biologic medication for the treatment of Crohn's disease,^[2] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF- α) and is manufactured by UCB.^{[3][4][5]}

1 Approvals and indications

Crohn's Disease On April 22, 2008, the U.S. FDA approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.^{[4][6][7]}

Rheumatoid arthritis On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA on October 1, 2009.^[8]

Psoriatic arthritis On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.^[9]

2 Method of action

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.^[10]

3 Clinical trials

Crohn's disease Positive results have been demonstrated in two phase III trials (PRECISE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.^{[2][10][11][12]}

Axial spondyloarthritis In 2013, a phase 3 double blind randomized placebo-controlled study found

significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.^[13]

Rheumatoid arthritis Certolizumab appears beneficial in those with rheumatoid arthritis.^[14]

4 Side effects

Significant side effects occur in 2% of people who take the medication.^[14]

5 References

- [1] Goel, Niti; Sue Stephens (2010). "Certolizumab pegol". *MAbs*. **2** (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560.
- [2] Sandborn WJ, Feagan BG, Stoinov S, et al. (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". *N. Engl. J. Med.* **357** (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458.
- [3] Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". *Expert opinion on biological therapy*. **5** (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.
- [4] index.cfm?fuseaction=Search.Label_ApprovalHistory "Cimzia Label and Approval History" Check url= value (help). *Drugs@FDA*. U.S. Food and Drug Administration (FDA). Retrieved 2009-11-15.
- [5] "Cimzia Prescribing Information" (PDF). US Food and Drug Administration (FDA). April 2016. Retrieved 2016-08-21.
- [6] UCB press release - Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease. Retrieved April 22, 2008.
- [7] Waknine, Yael (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Retrieved 2008-05-01.
- [8] "Cimzia European Public Assessment Report". European Medicines Agency. Retrieved November 15, 2009.
- [9] "Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis". Retrieved October 1, 2013.

- [10] Schreiber S. et al., Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (pre-cise), *Gut*, 2005, 54, suppl7, A82
- [11] Sandborn et al., Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECISE 1), *Gastroenterology*, 2006, 130, A107
- [12] "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease" (Press release). UCB. October 23, 2006. Retrieved 2009-11-15.
- [13] Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (May 2013). "PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study". *Value in Health*. **16** (3): A227. doi:10.1016/j.jval.2013.03.1150. Retrieved 2013-05-18.
- [14] Ruiz Garcia, V; Jobanputra, P; Burls, A; Cabello, JB; Vela Casasempere, P; Bort-Marti, S; Kynaston-Pearson, FJ (Sep 18, 2014). "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.". *The Cochrane database of systematic reviews*. **9**: CD007649. doi:10.1002/14651858.CD007649.pub3. PMID 25231904.

6 External links

- certolizumab pegol at the US National Library of Medicine Medical Subject Headings (MeSH)
- Cimzia Website

7 Text and image sources, contributors, and licenses

7.1 Text

- **Certolizumab pegol** *Source:* https://en.wikipedia.org/wiki/Certolizumab_pegol?oldid=749197724 *Contributors:* Chowbok, Rich Farmbrough, Arcadian, MichaelEdwardmarks, Sburke, GregorB, DePiep, Rjwilmsi, Stijn Calle, Asams10, Pegship, DVD R W, SmackBot, Chris the speller, Beetstra, Fvasconcellos, Cydebot, Thijs!bot, Mr.mendez, Nbauman, Rod57, Thijs07, BlakeCS, Doc James, Gor n bein, Carlo Banez, Stretchcat, Addbot, DOI bot, Luckas-bot, Yobot, CheMoBot, Anypodetos, Citation bot, Michael Chidester, Aztec Master, GrouchoBot, LucienBOT, Citation bot 1, Duckweedwz, BogBot, Jesse V., RjwilmsiBot, Dcirovic, PotatoBot, Med Chaos, Hazard-Bot, Peryeat, The chemistsd, Louisajb, Pashihiko, Mabsedit, BattyBot, TylerDurdin8823, Epicgenius, Monkbot, Wikiortholog and Anonymous: 16

7.2 Images

- **File:Lock-green.svg** *Source:* <https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg> *License:* CC0 *Contributors:* en:File:Free-to-read_lock_75.svg *Original artist:* User:Trappist the monk
- **File:X_mark.svg** *Source:* https://upload.wikimedia.org/wikipedia/commons/a/a2/X_mark.svg *License:* Public domain *Contributors:* Own work *Original artist:* User:Gmaxwell
- **File:Yes_check.svg** *Source:* https://upload.wikimedia.org/wikipedia/en/f/fb/Yes_check.svg *License:* PD *Contributors:* ? *Original artist:* ?

7.3 Content license

- Creative Commons Attribution-Share Alike 3.0